All Clinical Studies and Trials
Status
CoVPN 3006: A randomized controlled study to assess SARS CoV-2 infection, viral shedding, and subsequent potential transmission in individuals immunized with Moderna COVID-19 Vaccine

To evaluate the efficacy of Moderna COVID-19 vaccine compared to no vaccine against SARS-CoV-2 infection in young adults aged 18-29. 

https://redcap.uahs.arizona.edu/surveys/?s=CPPDY3HMKYCPKC7J

Elizabeth Connick, MD
Active
COVID-19: SARS Vaccination (SARS)

This is a multicenter, randomized, initially blinded (masked), phase 2 trial to assess SARS-CoV-2 vaccination reactions in two populations:

Active
(ACTIV-1 IM) Immune Modulators for Treating COVID-19

The research objectives are to evaluate each agent with respect to speed of recovery, mortality, illness severity, and hospital resource utilization

Marilyn Glassberg, MD
Active
Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19) (CX4945)

To evaluate safety and explore clinical benefits of Silmitasertib 1000 mg BID dose in patients with severe illness caused be SARS-COV-2.

Marilyn Glassberg, MD
Active
Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults (PassItOn)

To assess the safety and efficacy of convalescent donor plasma to treat COVID-19 in hospitalized adults in a randomized, placebo-controlled setting.

To evaluate clinical efficacy of convalescent plasma compared to placebo, among adults with COVID-19 requiring hospitalization.

Marilyn Glassberg, MD
Active
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 (CYNKCOVID)

To assess safety and efficacy of immunotherapy with delivery of of natural killer cells in treatment of patients with moderate COVID-19 disease.

Marilyn Glassberg, MD
Closed
Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19

This study is randomized trial to assess the effectiveness and safety of using combination therapy drugs in treating COVID-19 patients. This study is active, but closing soon.

 

Marilyn Glassberg, MD
Active
Anti-thrombotics for Adults Hospitalized With COVID-19 (ACTIV-4)
Dr. Afshin Sam and Joseph Bellal
Active
COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT
Drs. Sairam Parthasarathy and Franz Rischard
Active
Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19

To evaluate the safety and tolerability of REGN10933+REGN10987 compared to placebo

Dr. Billie Bixby and Sairam Parthasarathy
Active
Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19
Dr. Sachin Chaudhary
Closed
PRESCO (Predictors of Severe COVID-19 Outcomes)

Performance (discrimination / calibration) of models [ Time Frame: From date of study enrollment until the date of first documented ARDS diagnosis or date of death from any cause, whichever comes first, assessed up to study end (estimated at 3 months). ] Performance (discrimination / calibration) of models that predict the risk of development of ARDS and/or mortality among COVID-19 patients who

Dr. Sairam Parthasarathy
Active
Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry (COVID-19)

Researchers are creating a real time COVID-19 registry of current ICU/hospital care patterns to allow evaluations of safety and observational effectiveness of COVID-19 practices and to determine the variations in practice across hospitals.

Jarrod Mosier, MD
Active
Community-Engagement Research Alliance (CEAL) Against COVID-19 in Disproportionately Affected Communities
Dr. Sairam Parthasarathy
Active
BLUE - CORAL (Biology and Longitudinal Epidemiology of PETAL COVID-19 Observational Study)
Drs. Jarrod Mosier and Cameron Hypes
Active
COVID - PACT (Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial)

Primary Outcome Measures  :

  1. Primary endpoint: Venous or arterial thrombotic events [ Time Frame: 28 days or until hospital discharge, whichever earlier ]

    Hierarchical composite: Death due to venous or arterial thrombosis, pulmonary embolism, clinically evident DVT, type 1 MI, ischemic stroke, systemic embolism or acute limb ischemia, or clinically silent DVT

Dr. Jarrod Mosier
Closed
ACTIV-3
Dr. Jarrod Mosier
Active